Database→Retatrutide
Tier 1-2Weight LossMetabolicDiabetesPREMIUM

Retatrutide

Retatrutide (LY3437943) — Triple GIP/GLP-1/Glucagon Receptor Agonist
Investigational. Not FDA or EMA approved. Eli Lilly Breakthrough Therapy designation for T2D. TRIUMPH-4 Phase 3 (December 2025): first Phase 3 readout, obesity plus knee osteoarthritis, all primary and key secondary endpoints met, 28.7% weight loss at 68 weeks. TRIUMPH-1 Phase 3 (May 21, 2026): pivotal obesity trial, n=2,339, all doses met primary and key secondary endpoints: 28.3% at 12 mg, 25.9% at 9 mg, 19.0% at 4 mg at 80 weeks. 45.3% achieved 30% or more weight loss at 12 mg: highest ever in a pharmaceutical trial. Extension to 104 weeks: 30.3% mean loss (85.0 lbs). TRANSCEND-T2D-1 Phase 3 (Q1 2026): positive results in type 2 diabetes. FDA submission estimated Q4 2026 to Q1 2027. Potential approval late 2027. WADA: not prohibited.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist and the most clinically advanced compound in this series by a wide margin. TRIUMPH-1 Phase 3 results (May 21, 2026) confirmed 28.3% mean weight loss at 80 weeks in 2,339 participants at the 12 mg dose: the highest ever documented in a pharmaceutical obesity trial. 45.3% achieved 30% or more weight loss, a threshold historically associated only with bariatric surgery. 30.3% mean loss at 104 weeks in the extension cohort. TRIUMPH-4 (December 2025) demonstrated 28.7% weight loss plus 75.8% WOMAC pain score reduction in obesity with knee osteoarthritis. FDA submission estimated Q4 2026 to Q1 2027.

🔒

Full Profile: Premium Members Only

The complete Retatrutide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use